Jubilant Pharmova Intrinsic Value
Jubilant Pharmova (JUBLPHARMA) median intrinsic value is ₹1930.70 from 9 valuation models (range ₹290–₹2413), vs current price ₹965.35 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Read Jubilant Pharmova dividend policy for the complete payout history and dividend yield track record.
JUBLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Jubilant Pharmova intrinsic value across 9 models vs current price ₹965.35 — upside/downside and value range per method. For current market price and key ratios, visit JUBLPHARMA screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹664.40 | ₹531.52 - ₹797.28 | -31.2% | EPS: ₹30.20, Sector P/E: 22x |
| Book Value Method | asset | ₹2413.38 | ₹2172.04 - ₹2654.72 | +150.0% | Book Value/Share: ₹4433.12, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1930.70 | ₹1737.63 - ₹2123.77 | +100.0% | Revenue/Share: ₹5740.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1930.70 | ₹1737.63 - ₹2123.77 | +100.0% | EBITDA: ₹1328.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2413.38 | ₹1930.70 - ₹2896.06 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹289.61 | ₹260.65 - ₹318.57 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹466.59 | ₹419.93 - ₹513.25 | -51.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1930.70 | ₹1737.63 - ₹2123.77 | +100.0% | ROE: 6.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹1735.60 | ₹1562.04 - ₹1909.16 | +79.8% | EPS: ₹30.20, BVPS: ₹4433.12 |
JUBLPHARMA Intrinsic Value vs Market Price — All Valuation Models
Jubilant Pharmova fair value range ₹290–₹2413 vs current market price ₹965.35 across 9 valuation models. Analyse JUBLPHARMA shareholder distribution to track promoter, FII and institutional holdings.
JUBLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Jubilant Pharmova median intrinsic value ₹1930.70, current price ₹965.35 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of JUBLPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jubilant Pharmova (JUBLPHARMA) is ₹1930.70 (median value). With the current market price of ₹965.35, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹289.61 to ₹2413.38, indicating ₹289.61 - ₹2413.38.
Is JUBLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Jubilant Pharmova (JUBLPHARMA) appears to be trading below calculated value by approximately 100.0%.
JUBLPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Jubilant Pharmova financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.70 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 6.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JUBLPHARMA Cash Flow Quality — Operating & Free Cash Flow
Jubilant Pharmova operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,072 Cr | ₹1,072 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹971 Cr | ₹673 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹661 Cr | ₹424 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹838 Cr | ₹677 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,784 Cr | ₹1,421 Cr | Positive Free Cash Flow | 8/10 |